- Affordable Care Act (ACA)
- Beneficiary News
- Billing Tips
- Claim Form Updates
- CMC Submission
- Contract Drug List
- DUR Main Menu
- EPC Letters
- Fraud and Abuse
- LTC Rates Schedule
- Medi-Cal Comment Forum
- Medi-Cal Rates
- Medi-Cal & Telehealth
- Ordering, Referring and Prescribing (ORP)
- P/DCL List
- Provider Enrollment
- Provider-Preventable Conditions
- Quality and Accountability Supplemental Payment (QASP) Program
- Related Sites
- Suspended and Ineligible Provider List
- Technical Publications
- Trauma Screening Training Attestation
- User Guides
- Web Tool Box
Pharmacy Fee-For-Service Covered Outpatient Drugs FAQs
- Why did the Department of Health Care Services (DHCS) change its Medi-Cal fee-for-service pharmacy reimbursement for covered outpatient drugs?
The Centers for Medicare & Medicaid Services (CMS) published its Final Rule for Covered Outpatient Drugs (CMS-2345-FC) on February 1, 2016. Under the Final Rule, each state Medicaid agency was required to adopt an actual acquisition cost (AAC) based methodology for CODs. To satisfy this requirement, California, along with many other state Medicaid agencies, adopted CMS’s National Average Drug Acquisition Cost (NADAC) as the basis for AAC for drug ingredient reimbursement.
- When did these changes implement?
The reimbursement changes went live on February 23, 2019. Per the Final Rule, the new reimbursement methodologies were mandated to be effective April 1, 2017. Although State Plan Amendment (SPA) 17-002 was approved by CMS August 25, 2017, it took time for the state to update the claims processing system to reimburse using the new methodology. DHCS will make retroactive adjustments for impacted claims with dates of service from the policy effective date of April 1, 2017, through the implementation date of February 23, 2019. Additional FAQs for these adjustments will be added soon.
- What is the NADAC and how does CMS calculate it?
The NADAC is a national reference benchmark that state Medicaid programs may use when determining their reimbursement to pharmacy providers. It represents the national average invoice price derived from retail community pharmacies for drug products based on invoices from wholesalers and manufacturers. It does not reflect off-invoice discounts, rebates or price concessions. CMS has published its methodology for developing the NADAC for interested stakeholders. You may access the Methodology for Calculating the National Average Drug Acquisition Cost (NADAC) for Medicaid Covered Outpatient Drugs online.
- Is the AAC based on my own actual acquisition cost?
For non-340B pharmacy claims, the answer is no. NADAC is the national pricing benchmark developed by CMS that DHCS is using to represent AAC for reimbursement, not your individual pharmacy’s acquisition cost.
- Is Medi-Cal using the NADAC for both brand and generic drug products?
Yes, Medi-Cal is using the NADAC as the pricing benchmark for both brand and generic drug products.
- A NADAC price is not available for all drugs. What does Medi-Cal use as a backup benchmark when a NADAC price is not available?
When a NADAC price does not exist, Medi-Cal uses the Wholesale Acquisition Cost (WAC) + 0 percent as the price benchmark.
- Where can I access the NADAC pricing files to see if they cover my acquisition costs?
The NADAC pricing files are published weekly on the CMS Pharmacy Pricing website.
- I’ve noticed that sometimes my reimbursed amount is not the same as the NADAC price on the CMS file for a specific date of service. What should I do?
The CMS NADAC pricing files are updated in the Medi-Cal claims processing system as soon as they become available to the California Medicaid Management Information System (MMIS) Fiscal Intermediary (FI). Providers seeking an adjusted reimbursement may do so via the Claims Inquiry Form (CIF) process.
- The NADAC reimbursement does not cover my acquisition cost for certain drugs. What should I do?
If a provider determines that the NADAC reimbursement does not cover their acquisition cost for a drug, DHCS strongly urges those providers to immediately use the NADAC Request for Medicaid Reimbursement Review form to submit a rate review request to the CMS NADAC Help Desk. The CMS NADAC Help Desk will research inquiries and evaluate them for potential NADAC updates based upon invoice data collected from the provider initiating the review, additional pharmacy inquiries and other market factors such as compendia price changes. Without taking that action, no change will be considered to the NADAC for the drug in question.
- Why are drugs exempt from the Assembly Bill 97 10 percent reduction being paid with the new methodology? I thought these drugs were exempt from reductions?
Per state law, the 10 percent reduction from AB 97 was discontinued for all covered outpatient drugs with the implementation of the new reimbursement methodology.
- I have noticed that a drug product is no longer reimbursable that was reimbursable previously. What should I do?
There may be infrequent instances in which a NADAC, WAC or Federal Upper Limit (FUL) price is not on file for a specific National Drug Code (NDC) that was previously reimbursable. When this situation occurs, DHCS recommends Medi-Cal pharmacies dispense the prescribed medication available from an alternative manufacturer that is shown to be reimbursable under the new methodology.
- What has happened to the Maximum Allowable Ingredient Cost (MAIC) prices?
Although the MAIC, as authorized by Welfare and Institutions Code (W&I Code), Section 14105.45(b)(4), is part of the “lowest of” formula for drug ingredient reimbursement, DHCS has elected to discontinue all MAICs effective for dates of service on or after April 1, 2017, and to not implement any new MAICs for the time being. Providers will be notified a minimum of 30 days in advance if and when DHCS chooses to implement any new MAICs. Therefore, all products associated with a MAIC prior to April 1, 2017, no longer have an assigned MAIC effective April 1, 2017.
- Does SPA 17-002 modify the reimbursement methodology for blood factors?
No. DHCS did not include this specific change in SPA 17-002 due to policy requirements that are not yet finalized. Therefore, DHCS will include these changes in a subsequent SPA. Until then, Medi-Cal will continue to reimburse blood factor products at average sales price (ASP) + 20 percent.
- Why was the Long Term Care (LTC) dispensing fee removed?
The survey data reported by LTC pharmacies did not result in an average dispensing cost statistically different from the results of the two-tier professional dispensing fee structure. Therefore, there will no longer be a distinct dispensing fee for LTC pharmacies.
- Where can I find more information on the provider self-attestation for the two-tier dispensing fee?
Providers may refer to the Pharmacy Provider Self-Attestation FAQs for general instructions and a link to the Pharmacy Provider Self-Attestation portal.
- Why does the professional dispensing fee change at a total annual claim volume threshold of 90,000?
The decrease in the cost of dispensing flattened out for pharmacies filling more than 90,000 dispensed prescriptions each year, thus providing a natural demarcation point for dispensing fees. Please note that claims can be equated to prescriptions dispensed.
- How long will DHCS keep this new dispensing fee structure?
There is no predetermined duration identified with this new methodology. DHCS will retain this new methodology until circumstances dictate revisiting it.
- Why weren’t specialty pharmacies given their own dispensing fees as a result of this study?
The survey results for costs of dispensing did not justify the creation of professional dispensing fees unique to specialty pharmacies.
AAC and Ingredient Cost Reimbursement
Professional Dispensing Fee
If you cannot view the MS Word or PDF (Portable Document Format) documents correctly, please visit the Web Tool Box to link to a download site for the appropriate reader.